Publications by authors named "F Parthenakis"
Hypertrophic cardiomyopathy (HCM) is a heart muscle disease associated with an increased risk for sudden cardiac death (SCD). Cytokeratin 18-based proteins, such as M30 and M65 antigens, are known cell-death biomarkers. M30 antigen is released from cells during apoptosis, and M65 antigen is released during cell death from any cause, such as apoptosis or necrosis.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on pediatric cardiomyopathy in children under 18 in Crete, Greece, aiming to assess its epidemiology from 2002 to 2022.
- The annual incidence was found to be 1.59 cases per 100,000 children, with dilated cardiomyopathy being the most common type (50%).
- The research indicates a higher incidence of pediatric cardiomyopathy in Crete compared to other Caucasian populations, suggesting a need for further examination of genetic factors in this demographic.
Purpose: Atrial fibrillation (AF) and heart failure (HF) are common and commonly coexisting cardiovascular diseases in hospitalized patients. We report the absolute number and interrelation between AF and HF, assess the daily burden of both diseases on the healthcare system, and describe the medical treatment in a real-world, nationwide conducted snapshot survey.
Methods: A questionnaire was equally distributed to various healthcare institutions.
Post-PCI corrected TIMI Frame Count predicts left ventricular global longitudinal strain at 90 days post-STEMI in thrombolysis-treated patients: A pre-specified analysis of the MIRTOS study.
Am Heart J Plus
November 2022
Article Synopsis
- - Ticagrelor is recommended for STEMI patients receiving primary PCI, but its effectiveness in conjunction with thrombolysis has not been well-researched, prompting this study comparing it to clopidogrel after 90 days post-STEMI.
- - The study analyzed changes in left ventricular ejection fraction (ΔLVEF) and left ventricular longitudinal strain (ΔLV-GLS) in patients, finding no significant differences between the two drugs concerning these outcomes.
- - It was concluded that both ticagrelor and clopidogrel lead to similar myocardial recovery, and that the corrected TIMI Frame Count (CTFC) post-PCI is a potential predictor of long-term heart function in patients treated with throm
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have changed the clinical landscape of diabetes mellitus (DM) therapy through their favourable effects on cardiovascular outcomes. Notably, the use of SGLT2i has been linked to cardiovascular benefits regardless of DM status, while their pleiotropic actions remain to be fully elucidated. What we do know is that SGLT2i exert beneficial effects even at the level of the myocardial cell and that these are linked to an improvement in the energy substrate, resulting in less inflammation and fibrosis.
View Article and Find Full Text PDF